SeraCare Life Sciences divests Biorepository business

SeraCare Life Sciences, a portfolio company serving the in vitro diagnostics and clinical laboratory markets, today announced that it has sold its biorepository, biobanking and laboratory services business to Precision Health Holdings, Inc.

This content was submitted directly to this website by the supplier.

 SeraCare Life Sciences, a portfolio company of Linden Capital Partners serving the in vitro diagnostics and clinical laboratory markets, today announced that it has sold its biorepository, biobanking and laboratory services business to Precision Health Holdings, Inc. This Maryland-based business includes biorepository and biobanking services, AccuCell® products and certain laboratory services.

“The sale of our Biorepository business is an important element in our growth strategy for SeraCare,” said Charles Mamrak, CEO of SeraCare. “We can now more freely serve our growing customer base in the in vitro diagnostics market and execute on our mission of improving quality of life by advancing a global understanding of disease.”

The transaction includes the transfer of Biorepository assets and employees. Financial terms of the transaction were not disclosed. SeraCare Life Sciences was advised by BroadOak Partners LLC and Kirkland & Ellis LLP during the transaction.

More in Home